Monday, February 8, 2016

Titan Medical prices overnight offering

Titan Medical prices overnight offering

February 5, 2016 by · Leave a Comment 

Tweet Titan Medical (OTCQX:TITXF; TSX:TMD) has priced an overnight marketed offering of equity securities, issuing up to 8,888,889 units at a price of 90 cents each for gross proceeds of about $8-million. Each unit consists of one common share of the company and one warrant. Each warrant is exercisable at a price of $1 to […]

Microbix developing program to combat Zika virus

Microbix developing program to combat Zika virus

February 5, 2016 by · Leave a Comment 

Tweet Microbix Biosystems (TSX:MBX) has made plans to develop and introduce new products for use in diagnostic tests and vaccine research in response to the emergent Zika virus, which is spreading throughout the Americas and is being characterized as a crisis by health authorities. The Zika virus is a member of the flavivirus family, which […]

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium reaches 75% enrolment in Phase 3 trials

February 4, 2016 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical Phase 3 trials, with 180 patients per clinical trial. They are being conducted under a SPA with the FDA […]

Roth starts Bionomics at buy

Roth starts Bionomics at buy

February 3, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday. “We believe a significant disconnect exists on the [company’s] BNC210 opportunity alone based on clinical data in hand and the partnering potential around a drug that could address […]

Diamedica in talks with Chinese pharma to develop DM199

Diamedica in talks with Chinese pharma to develop DM199

February 2, 2016 by · Leave a Comment 

Tweet Diamedica (OTCQB:DMCAF; TSX-V:DMA) has commenced discussions for a potential collaboration with Chinese pharmaceutical firms for the development and commercialization of its DM199 drug candidate. DM199 is potentially a replacement of the approved urine-derived kallikrein-1 protein, or Kailikang, in Southeast Asia for the treatment of acute ischemic stroke. DM199 is a recombinant form of the […]

Leerink downgrades Carbylan to market perform

Leerink downgrades Carbylan to market perform

February 2, 2016 by · Leave a Comment 

Tweet Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for Hydros-TA in the COR 1.1 trial. The shares were down 46% to $1.33 in after-market trading on Monday. The company’s lead program, Hydros-TA, […]

Knight to sublicense Titan Pharma’s Probuphine in Canada

Knight to sublicense Titan Pharma’s Probuphine in Canada

February 1, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to commercialize Titan’s Probuphine in Canada. Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention, as well […]

Transition Therapeutics reports TT401 trial results

Transition Therapeutics reports TT401 trial results

February 1, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects […]

Rodman starts VolitionRx at buy

Rodman starts VolitionRx at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and […]

Rodman starts EyeGate Pharma at buy

Rodman starts EyeGate Pharma at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday. “In our view, the company’s EGP-437 combination product is differentiated from eye drops and intraocular injections in that it is non-invasive and solves patient non-compliance and […]

Next Page »

Email Newsletters with Constant Contact
Google+